Creatio, partner of CataloniaBio & Health Tech and production and validation centre for advanced therapies of the University of Barcelona, through the Bosch i Gimpera Foundation, has acquired UTOX, the experimental toxicology platform of the Barcelona Science Park (PCB). The aim of this acquisition is for UTOX to be integrated into the Creatio technology development centre, a leader in advanced therapies and a member of the TECNIO network.
Thus, from 1 July, Creatio will expand its portfolio of services by offering preclinical studies through the incorporation of the PCB experimental toxicology platform. This acquisition will allow Creatio to offer support and services along the entire drug development chain, from basic research to the production of advanced therapy drugs.
Preclinical toxicology studies assess the potential adverse effects of new drugs and/or other external agents such as chemicals by analysing how they interact with the body. These studies allow the determination of the optimal dose, frequency of administration and side effects, among others, as a necessary step for future application.
Josep M. Canals, Director of Creatio and Professor in the Department of Biomedicine at the University of Barcelona, expressed his satisfaction with this strategic acquisition. "Thanks to the acquisition of the experimental toxicology platform at the Barcelona Science Park, Creatio now contributes to the entire drug development chain by incorporating toxicology studies that are critical for patient safety. "We are committed to delivering high-quality results across the entire ecosystem to ensure the confidence and efficacy of these innovative therapies," said Canals.
Maria Terrades, CEO of the Barcelona Science Park, stressed the importance of the acquisition to reinforce the scientific and technical offer provided by the park. "It was crucial that Creatio decided to keep the physical laboratory at the Barcelona Science Park," said Terrades. "This will allow Creatio to be close to companies and organisations in the PCB community, strengthening our community and fostering collaboration and knowledge transfer between the public and private sectors.
Creatio is a translational research centre that has the TECNIO seal as a technology development centre. With the addition of the experimental toxicology platform, Creatio will become one of the most relevant TECNIO centres in the biomedical field. With this expansion, Creatio expects to be a key member of the public and private ecosystem in Catalonia and Spain.
Comments